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Brain metastases (BM) will be diagnosed in 
15-35% of patients with breast cancer (BC) [1–3]. The 
occurrence of BM is also linked to tumor biology; 
BM are more common in patients with triple negative 
BC (TNBC) and those positive for the human epider-
mal growth factor receptor 2 (HER2) [4–5]. 
AbstrAct
background: This study quantified clinical outcomes by molecular subtype of metastatic breast cancer (Bc) following whole 
brain radiation therapy (WBrT) or stereotactic radiosurgery (srs). Doing so is important for patient counseling and to assess 
the potential benefit of combining targeted therapy and brain radiotherapy for certain molecular subtypes in ongoing trials. 
Materials and methods: The National cancer Database was queried for Bc (invasive ductal carcinoma) cases receiving brain 
radiotherapy (divided into WBrT and srs). statistics included multivariable logistic regression to determine factors associated 
with srs delivery, Kaplan-Meier analysis to evaluate overall survival (Os), and cox proportional hazards modeling.
results: Of 1,112 patients, 186 (16.7%) received srs and 926 (83.3%) underwent WBrT. altogether, 410 (36.9%), 195 (17.5%), 
162 (14.6%), and 345 (31.0%) were er+/her2–, er+/her2+, er–/her2+, and er–/her2–, respectively. In the respective mo-
lecular subtypes, the proportion of subjects who underwent srs was 13.4%, 19.4%, 24.1%, and 15.7%. respective Os for WBrT 
patients were 12.9, 22.8, 10.6, and 5.8 months; corresponding figures for the srs cohort were 28.3, 40.7, 15.0, and 12.9 months 
(p < 0.05 for both). When comparing Os between treatment different histologic subtypes, patients with er-/her2+ and  
er–/her2– disease had worse Os than patients with er+/her2– disease, for both patients treated with srs and for patients 
treated with WBrT.
conclusions: Molecular subtype may be a useful prognostic marker to quantify survival following srs/WBrT for metastatic Bc. 
patients with her2-enriched and triple-negative disease had the poorest survival following brain irradiation, lending credence 
to ongoing studies testing the addition of targeted therapies for these subtypes.
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Management of BM requires strong multidisci-
plinary coordination, as options include resection, 
systemic therapy, and/or radiation therapy (RT). 
With regard to the latter, the historic standard 
of care has been whole brain RT (WBRT), which 
addresses microscopic foci of disease not appar-
ent on diagnostic imaging. However, its utility is 
beginning to be gradually replaced by stereotac-
tic radiosurgery (SRS), which can deliver abla-
tive doses for potentially higher local control, and 
significantly reduces the neurocognitive deterio-
ration observed with use of WBRT [6]. Chemo-
therapy agents have traditionally not been utilized 
for primary therapy of brain disease, as penetra-
tion through the blood-brain barrier is generally 
low. Targeted agents such as trastuzumab, poly 
ADP ribose polymerase inhibitors, tyrosine kinase 
inhibitors (TKIs), and immune checkpoint inhibi-
tors (ICIs) show modest central nervous system 
(CNS) activity, but may not reduce the incidence 
of BM [7].
Given the multitude of options for BC patients 
with various molecular subtypes, expected out-
comes following WBRT or SRS for each subtype 
are important to quantify. In addition to having im-
plications on patient counseling, it may also serve 
to assess the potential benefit of combining targeted 
therapy and brain RT for certain subtypes. There 
are two ongoing randomized phase II trials of the 
latter concept: Radiation Therapy Oncology Group 
(RTOG) 1119 is evaluating lapatinib in HER2 pa-
tients undergoing WBRT/SRS (NCT01622868), 
and Southwest Oncology Group (SWOG) 1416 is 
examining veliparib for TNBC with or without BM 
(NCT02595905). In order to accomplish this goal, 
we evaluated the large, contemporary National 
Cancer Database (NCDB).
Materials and methods
The NCDB is a joint project of the Commission 
on Cancer (CoC) of the American College of Sur-
geons and the American Cancer Society, which con-
sists of de-identified information regarding tumor 
characteristics, patient demographics, and patient 
survival for approximately 70% of the US popula-
tion [8]. All pertinent cases are reported regularly 
from CoC-accredited centers and compiled into 
a unified dataset, which is then validated. The data 
used in the study were derived from a de-identified 
NCDB file (2005–2014). The American College of 
Surgeons and the CoC have not verified and are 
neither responsible for the analytic or statistical 
methodology employed nor the conclusions drawn 
from these data by the investigators. As all patient 
information in the NCDB database is de-identified, 
this study was exempt from institutional review 
board evaluation.
Inclusion criteria for this study were women 
with invasive ductal carcinoma with Stage IV (M1) 
breast cancer (International Classification of Dis-
ease–0–3 code 8500) who received RT to the brain. 
Additionally, because the goal of this study was to 
evaluate outcomes by molecular subtype, subjects 
were required to have available information re-
garding estrogen receptor (ER) and HER2 status. 
The patients were divided into two cohorts based 
on type of radiation delivered: SRS or WBRT. 
Based on criteria used in existing studies [9-11], 
patients included in the SRS cohort were those 
who were coded as received “gamma knife radio-
surgery”, “LINAC radiosurgery,” or “stereotactic 
radiosurgery, NOS (not otherwise specified);” or, 
those receiving a daily fraction dose ≥ 6 Gy in ≤ 5 
fractions. All other patients were categorized as the 
WBRT cohort. In accordance with the variables in 
NCDB files, information collected on each patient 
broadly included demographic, clinical, and treat-
ment data. 
All statistical tests were two-sided, with a defini-
tion of p < 0.05 for statistical significance, and were 
performed using STATA (version 14, College Sta-
tion, TX). Multivariable logistic regression model-
ing determined characteristics predictive for SRS 
administration. Overall survival (OS, the interval 
between the date of diagnosis of brain metastasis 
and the date of death, or censored at last contact) 
analysis was per the Kaplan-Meier method, with 
group comparisons done with the log-rank test. 
Survival was separately calculated when dividing 
patients by histologic subtype for both WBRT and 
SRS. Following univariate analysis to determine 
factors associated with overall survival, Cox multi-
variate analysis included variables that were either 
significant or showed a strong trend to statistical 
significance on univariate analysis. Patients with-
out complete survival information were censored 
from the survival analyses. The proportional haz-
ards assumption was checked graphically using 
log-log plots. 
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results
A complete patient selection diagram is shown in 
Figure 1. Overall, 1,112 patients met selection cri-
teria (Tab. 1); 186 (16.7%) underwent SRS and 926 
(83.3%) received WBRT. Altogether, 410 (36.9%), 
195 (17.5%), 162 (14.6%), and 345 (31.0%) of the pa-
tients had ER+/HER2–, ER+/HER2+, ER–/HER2+, 
and ER–/HER2– disease, respectively.
Over the study period, utilization of SRS and 
WBRT by molecular subtype is given in Figure 2; 
16.7% of the overall cohort received SRS, and 
83.3% WBRT. In the respective molecular sub-
types, the proportion of subjects who underwent 
SRS was 13.4%, 19.4%, 24.1%, and 15.7%. SRS 
was more often administered to ER–/HER2+ 
cases, at academic centers, in more recent time 
periods, and to privately-insured subjects (rela-
National Cancer Data Base
Stage IV breast cancer 
Diagnosed 2005–2014 
(n = 79,875)
Excluded (n = 78,763)
Non invasive ductal histology (n = 29,564)
No radiation to the brain (n = 48,172)
No record of ER/ HER2 (n = 1,027)            
Study population (n = 1,112)
Figure 1. patient selection diagram
table 1. Demographic and clinical characteristics for all patients
Characteristic
Stereotactic radiosurgery 
(n = 186) 




≤ 50 58 (31.2%) 235 (25.4%) 0.215
51–65 85 (45.7%) 76 (51.4%)
66–75 27 (14.5%) 55 (16.7%)
≥ 76 16 (8.6%) 60 (6.5%)
Molecular subtype
er+her2– 55 (29.6%) 355 (38.3%) 0.013
er+her2+ 38 (20.4%) 157 (17.0%)
er–her2+ 39 (21.0%) 123 (13.3%)
er–her2– 54 (29.0%) 291 (31.4%)
race
White 147 (79.0%) 711 (76.8%) 0.376
Black 26 (14.0%) 164 (17.7%)
Other 13 (7.0%) 51 (5.5%)
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tive to Medicaid/uninsured) (p < 0.05 for all) 
(Tab. 2).
Figure 3A displays OS by molecular subtype 
in patients status post WBRT. The median OS for 
each molecular group amongst patients treated with 
WBRT was 12.9, 22.8, 10.6, and 5.8 months for pa-
tients with ER+HER2–, ER+HER2+, ER–HER2+, 
and ER–HER2– disease, respectively. When compar-
ing OS amongst patients receiving WBRT, those with 
ER+HER2+ disease had the greatest median OS when 
table 1. Demographic and clinical characteristics for all patients
Characteristic
Stereotactic radiosurgery 
(n = 186) 




0 158 (85.0%) 762 (82.2%) 0.639
1 20 (10.8%) 122 (13.2%)
≥ 2 8 (4.3%) 43 (4.6%)
Median Income
≤ 62999 UsD 133 (71.5%) 684 (73.9%) 0.633
≥ 63000 UsD 52 (28.0%) 233 (25.2%)
Not recorded 1 (0.5%) 9 (1.0%)
Facility type
academic 78 (41.9%) 24 (30.7%) 0.005
Nonacademic 92 (49.5%) 576 (62.2%)
Not reported 16 (8.6%) 66 (7.1%)
chemotherapy
Yes 129 (69.4%) 571 (61.7%) 0.106
No 41 (22.0%) 236 (25.5%)
Not recorded 16 (8.6%) 119 (12.9%)
Grade
Well differentiated 5 (2.7%) 20 (2.2%) 0.318
Moderately differentiated 42 (22.6%) 242 (26.1%)
poorly differentiated/anaplastic 104 (55.9%) 528 (57.0%)
Not recorded 35 (18.8%) 136 (14.7%)
Year of diagnosis
2005–2011 63 (33.9%) 404 (43.6%) 0.014
2012–2014 123 (66.1%) 522 (56.4%)
Insurance
private 95 (51.1%) 370 (40.0%) 0.001
Medicaid 30 (16.1%) 202 (21.8%)
Medicare 55 (29.6%) 246 (26.6%)
Not insured 5 (2.7%) 87 (9.4%)
Other/not recorded 1 (0.5%) 21 (2.3%)
surgery
No surgery 143 (76.9%) 766 (82.7%) 0.020
Lumpectomy 10 (5.4%) 62 (6.7%)
Mastectomy 33 (17.7%) 98 (10.6%)
































Figure 2. Utilization of stereotactic radiosurgery (srs) by histologic subtype 
table 2. Multivariable logistic regression analysis for factors predictive of receiving stereotactic radiosurgery
Characteristic Odds ratio 95% confidence interval p-value
Age
≤ 50 1 (reference)
51–65 0.680 0.440–1.050 0.082
66–75 0.555 0/274–1.124 0.102
≥ 76 0.906 0.398–2.065 0.814
Molecular subtype
er+her2– 1 (reference)
er+her2+ 1.493 0.912–2.446 0.111
er–her2+ 1.944 1.154–3.276 0.012
er–her2– 1.219 0.774–1.921 0.392
race
White 1 (reference)
Black 0.845 0.523–1.364 0.490
Other 1.187 0.608–2.320 0.616
charlson Deyo score
0 1 (reference)
1 0.746 0.438–1.269 0.280
≥ 2 0.908 0.399–2.069 0.818
Median income
≤ 62999 UsD 1 (reference)
≥ 63000 UsD 1.001 0.688–1.455 0.997
Not recorded 0.718 0.086–6.011 0.760
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compared to any other histologic subtype (p < 0.005 
for all). In the SRS cohort (Fig. 3B), respective OS 
were 28.3, 40.7, 15.0, and 12.9 months. Patients with 
ER+HER2+ disease had greater median OS 
In the overall cohort, there were several predic-
tors of OS (Tab. 3) such as age, facility type, any 
local surgery, use of SRS, and chemotherapy receipt 
(p < 0.05 for all). Notably, as compared to ER+/
HER2– disease, ER–/HER2– and ER–/HER2+ cases 
were associated with poorer OS (p ≤ 0.001 for both). 
Discussion
Management of BM, especially from BC, con-
tinues to evolve. This study of a large, contempo-
rary national database quantifies survival by mo-
lecular subtype following SRS or WBRT. Patients 
with HER2-enriched disease and ER-HER2- had 
the poorest survival following brain irradiation, 
lending credence to multiple ongoing randomized 
phase II studies testing the addition of targeted 
therapies for these high-risk subtypes. 
Our results support other data demonstrating 
that molecular subtypes of BC represent distinct 
biological entities with distinct areas of metastases, 
patterns of failure, and survival [4–5, 12]. Moreover, 
it supports the disease-specific graded prognostic 
assessment posited by Sperduto and colleagues, as 
well as the recent update describing improved OS 
in patients with HER2 disease, although that study 
table 2. Multivariable logistic regression analysis for factors predictive of receiving stereotactic radiosurgery
Characteristic Odds ratio 95% confidence interval p-value
Facility type
academic 1 (reference)
Nonacademic 0.555 0.390–0.789 0.001
Not reported 0.656 0.327–1.316 0.235
chemotherapy
Yes 1 (reference)
No 0.939 0.598–1.475 0.785
Not recorded 0.783 0.423–1.425 0.423
Grade
Well differentiated 1 (reference)
Moderately differentiated 0.635 0.218–1.854 0.406
poorly differentiated/anaplastic 0.595 0.208–1.701 0.332
Not recorded 0.849 0.285–2.530 0.769
Year of diagnosis
2005–2011 1 (reference)
2012–2014 1.493 1.055–2.113 0.024
Insurance
private 1 (reference)
Medicaid 0.582 0.366–0.925 0.022
Medicare 1.168 0.671–2.032 0.583
Not insured 0.245 0.095–0.630 0.004
Other/not recorded 0.223 0.029–1.171 0149
surgery
No surgery 1 (reference)
Lumpectomy 1.029 0.501–2.111 0.938
Mastectomy 1.805 1.122–2.903 0.015
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Figure 3. Kaplan-Meier curves comparing overall survival. A. all patients following whole brain radiation therapy. 
b. all patients following stereotactic radiosurgery
a B









srs 1 (reference) 1 (reference)
Whole brain 1.709 1.366–2.138 <0.001 1.673 1.325–2.111 < 0.001
Age
≤ 50 1 (reference) 1 (reference)
51–65 1.221 1.015–1.470 0.034 1.109 0.901–1.364 0.330
66–75 1.760 1.393–2.224 <0.001 1.188 0.846–1.667 0.319
≥ 76 2.702 1.976–3.696 <0.001 2.297 1.536–3.435 < 0.001
Molecular subtype
er+her2– 1 (reference) 1 (reference)
er+her2+ 0.638 0.501–0.812 <0.001 0.805 0.625–1.036 0.092
er–her2+ 1.115 0.886–1.405 0.353 1.515 1.179–1,948 0.001
er–her2– 2.133 1.783–2.553 <0.001 2.684 2.200–3.273 <0.001
race
White 1 (reference) – – –
Black 1.106 0.913–1.340 0.302 – – –
Other 0.838 0.597–1.174 0.304 – – –
charlson Deyo score
0 1 (reference) 1 (reference)
1 1.249 1.004–1.553 0.046 0.907 0.724–1.137 0.397
> 2 2.254 1.575–3.226 <0.001 1.348 0.927–1.959 0.118
Median income
≤ 62 999 UsD 1 (reference) 1 (reference)
≥ 63 000 UsD 0.756 0.631–0.905 0.002 0.835 0.693–1.006 0.058
Not recorded 2.407 1.243–4.664 0.009 1.798 0.912–3.544 0.090
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did not stratify for receipt of WBRT versus SRS 
[13, 14]. Although not provided by the NCDB, it 
would certainly be useful to further elucidate the 
rate of distant brain failure (DBF) following SRS 
for each molecular subtype. Reducing the rate of 
DBF is the strength of WBRT over SRS [15–17], but 
comes at the expense of greater neurocognitive dys-
function. For these purposes, approaches such as 
hippocampal-sparing WBRT have been developed 
(NCT02360215), but in order to evaluate judicious 
utilization, studies on the risk of DBF for each mo-
lecular subtype may further sharpen patient selec-
tion for these new technological approaches.
Likewise, because DBF may be differentially 
likely based on a molecular subtype, the ongoing 
debate of SRS versus WBRT may also be differen-
tially applicable. Although most data on SRS have 
utilized up to 3–4 BM [15–17], an argument for 
treating up to 10 tumors can certainly be made [18] 
in the sense that survival following SRS of 2–4 BM 
and 5–10 BM is statistically similar. To this extent, 
the trend towards higher DBF in patients initially 
presenting with higher numbers of BM may simply 
lead to a higher re-treatment rate but no change in 
outcomes; however, this notion has not been stud-
ied to date for each BC molecular subtype. 









academic 1 (reference) 1 (reference)
Nonacademic 1.186 1.010–1.394 0.038 1.179 1.001–1.389 0.049
Not reported 0.754 0.528–1.077 0.120 1.771 1.381–2.271 < 0.001
chemotherapy
Yes 1 (reference) 1 (reference)
No 1.408 1.182–1.677 <0.001 1.466 1.191–1.804 <0.001
Not recorded 1.828 1.451–2.304 <0.001 1.771 1.381–2.271 <0.001
Grade
Well differentiated 1 (reference) – – –
Moderately differentiated 1.161 0.646–2.087 0.617 – – –
poorly differentiated/
anaplastic
1.604 0.903–2.850 0.107 – – –
Not recorded 1.345 0.739–2.450 0.332 – – –
Year of diagnosis
2005–2011 1 (reference) – – –
2012–2014 0.931 0.800–1.085 0.360 – – –
Insurance
private 1 (reference) 1 (reference)
Medicaid 1.093 0.894–1.336 0.387 1.024 0.834–1.258 0.820
Medicare 1.763 1.463–2.123 <0.001 1.279 0.966–1.694 0.086
Not insured 1.371 1.042–1.805 0.024 1.150 0.868–1.522 0.330
Other/not recorded 1.406 0.835–2.368 0.200 1.152 0.675–1.964 0.604
surgery
No surgery 1 (reference) 1 (reference)
Lumpectomy 1.035 0.766–1.398 0.824 0.680 0.498–0.928 0.015
Mastectomy 0.703 0.558–0.886 0.003 0.679 0.533–0.866 0.002
srs — stereotactic radiosurgery
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The NCDB contains adequate information for 
an OS comparison between SRS and WBRT. In the 
present study, use of SRS was associated with an 
improved OS when compared to WBRT in both 
univariate and multivariate analysis. However, this 
does not necessarily mean that the improved OS 
was due to use of SRS. There are other confounding 
factors at play in the selection of SRS versus WBRT, 
including both the number of brain metastases, 
patient performance status, extracranial disease 
status, and technology available at the treatment 
facility, which can also have an impact on clinical 
outcome. Additionally, the finding that any local 
surgery, including either lumpectomy or mastec-
tomy, was associated with improved OS when com-
pared to no local surgery is in line with the findings 
of other published reports [19, 20].  Again, this 
finding may also be confounded by selection bias, 
in which more healthy patients with metastatic dis-
ease may have been more likely to undergo surgical 
therapy. Indeed, an early report of a randomized 
trial comparing local therapy to no local therapy 
in patients with newly diagnosis Stage IV breast 
cancer showed no OS benefit with the use of local 
therapy [21]. 
Although a major shortcoming of the NCDB is 
the lack of information regarding specific targeted 
agents (e.g. trastuzumab or lapatinib, which could 
explain why the ER+/HER2+ patients had nu-
merically higher OS than the ER+/HER2– cases), 
an emerging modality for management of BM 
are immune checkpoint inhibitors (ICIs). A dedi-
cated phase II study of ipilimumab for melanoma 
metastases showed a 24% intracerebral response 
rate for asymptomatic BM [22]. Additional-
ly, there is data now supporting a combination 
therapy of ICIs with ipilimumab and nivolumab 
that can control BM and potentially improve OS 
for these patients [23]. Although these data can-
not be extrapolated to the BC setting, they have 
often been utilized as justification to defer SRS 
pending greater necessity, or spare the patient 
of WBRT-related neurocognition. However, we 
posit that the response rate remains altogether 
low even for small, asymptomatic lesions, far 
lower than for SRS (or WBRT) alone, which must 
be weighed against the substantially increased 
cost of ICIs as compared to RT [24–25]. A ret-
rospective multicenter study studying up-front 
TKIs versus intracranial RT for EGFR-mutated 
non-small cell lung cancer showed a detriment to 
OS and trend towards a detriment to intracranial 
progression-free survival if intracranial RT was 
not delivered up-front [26]. Moreover, a recent 
study demonstrated that tucatinib, an oral TKI 
selective for HER2, can improve OS in patients 
with HER2+ breast cancer and BM, though future 
studies will be required to determine how best 
to incorporate intracranial RT and tucatinib to 
maximize OS while minimizing neurocognitive 
toxicity in this patient cohort [27]. 
The NCDB has numerous shortcomings [28–32], 
and the reader is advised that these data are merely 
hypothesis-generating and not intended to substi-
tute for randomized evidence. This includes a lack 
of information regarding the size/volume and loca-
tion of brain and systemic metastases, symptom-
atology, graded prognostic assessment class, diag-
nostic and follow-up workup (including magnetic 
resonance imaging), performance status, specific 
systemic therapy agents/dose/tolerance, salvage 
therapies, and other non-OS endpoints. This study 
also did not evaluate timing of SRS/WBRT from 
diagnosis, which could also alter conclusions. The 
sample sizes were also relatively small, especially 
in the SRS group, preventing robust matched OS 
analysis. Lastly, although the NCDB includes data 
for 70% of the US population, only CoC-accredited 
facilities contribute data; as a result, these findings 
may not necessarily be representative of the entire 
United States population.
conclusions
Management of BM, especially from BC, contin-
ues to evolve. This study of a large, contemporary 
national database quantifies survival by molecu-
lar subtype following SRS or WBRT. Patients with 
HER2-enriched disease and TNBC had the poorest 
survival following brain irradiation, lending cre-
dence to multiple ongoing randomized phase II 
studies testing the addition of targeted therapies for 
these high-risk subtypes. 
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